Biotech Co.** (Country) |
Pharma Co. |
Type/Product Area |
Amount |
Terms/Details (Date) |
Access Pharmaceuticals Inc. |
Block Drug Co. (NASDAQ: (OTC BB:AXCS) |
License agreement granting Access rights to Block's BLOCA) amlexanox (FDA-approved for aphthous ulcers) for use in chemotherapy- and radiation-induced mucositis; IND filed in indication |
ND |
Access to make up-front licensing payment and will make further payments based upon achievement of milestones; Access has no ongoing royalty obligations; agreement subject to receipt of final written consent from Takeda Chemical Industries Ltd. (Japan) (1/11) |
Agennix Inc.* |
Santen Pharmaceutical Co. Ltd. (Japan) |
Development of Agennix's recombinant human lactoferrin in the treatment of dry eye disease |
$5.9M |
Agennix to receive up to $5.9M plus royalties on net sales; Santen receives exclusive worldwide marketing rights (2/24) |
Alexion Pharmaceuticals Inc. |
Procter & Gamble (NYSE:PG) |
Collaboration to develop and commercialize Alexion's lead C5 complement inhibitor, 5G1.1-SC, currently in Phase IIb trials for patients undergoing cardiopulmonary bypass |
$95M |
Alexion to receive up to $95M in total payments, including up to $39M in pre-commercialization milestones; Alexion retains rights to commercial manufacturing and co-promotion in the U.S. (1/26) |
AlphaGene Inc.* |
NEN Life Science Products |
AlphaGene to develop Micromax System, gene expression arrays on glass slides; product is an integrated system of micro-arrays and reagents needed for differential gene expression analysis, including NEN's TSA signal amplification system and AlphaGene's FLEX (full length expressed gene technology) |
ND |
Long-term agreement providing NEN exclusive marketing rights to Micromax System, with four microarrays planned for 1999; further details ND (3/15) |
The Althexis Company Inc.* |
Pliva d.d. (Croatia) |
Collaboration to develop and commercialize antibiotics using Althexis' structure-based design technologies |
$14.4M |
Althexis to receive up to $14.4M over 3 years in research funding and mile stone payments; Pliva receives worldwide marketing rights to any drugs resulting from research focused on 2 specified antibacterial targets, with the exceptions of Japan, South Korea and Taiwan, where Althexis retains rights, and China, where the partners will co-promote (3/11) |
AMRAD Corp. Ltd. (NASDAQ:AMDJY; Australia) and the Ludwig Institute for Cancer Research (Zurich) |
RPR Gencell (division of Rhone-Poulenc Rorer; NYSE: RP) |
Rhone-Poulenc licensed VEGF-B (vascular endothelial growth factor B) gene patents and technology for use in cardiovascular disease |
ND |
ND (3/1) |
AMRAD Corp. Ltd. (NASDAQ:AMDJY; Australia) |
Glaxo Wellcome plc (NYSE:GLX; U.K.) |
AMRAD to supply rapid point-of-care diagnostic tests for companion marketing with Glaxo hepatitis B medicines, including Zeffix (lamivudine) |
ND |
Glaxo will purchase HBV test for sale and marketing under Glaxo Wellcome name (2/4) |
Anesta Corp. |
Novartis AG (Switzerland) |
Option agreement on Anesta's Oral Transmucosal System for drug delivery; option combines system with undisclosed compounds that may lead to 1 or more product candidates |
ND |
Partners will assess potential products, with the goal of identifying those worthy of licensing agreement (2/23) |
Aurora Biosciences Corp. |
Becton Dickinson Co. (NYSE:BDX) |
Becton to use Aurora's GenomeScreen to identify gene targets |
ND |
Aurora will receive research funding; parties will evaluate opportunities for future commercialization; further details ND (3/22) |
F. HoffmannLa Roche Ltd. (Switzerland) |
Aurora will provide a dedicated screen development and technology transfer resource to Roche; deal covers development of screens for up to 12 Roche targets in the first year |
ND |
Roche will make payments for screen development, technology transfer services and licenses, and will also make R&D payments to Aurora for compounds identified through screens generated in the collaboration, and royalties upon commercialization of compounds (2/22) |
|
Pharmacia & Upjohn Inc. (NYSE:PNU) |
Aurora to provide assay development and screening services to P&U; initial focus is to develop assays using Aurora's high-sensitivity fluorescent assay technology for a number of orphan G-protein coupled receptors identified by P&U; Aurora will also screen P&U compound libraries for hits |
ND |
P&U will fund a dedicated assay development team at Aurora; Aurora will provide screening services for some of the assays developed for P&U at a predetermined minimum level and for a separate fee; Aurora could also receive milestones and royalties (2/8) |
|
AutoImmune Inc. |
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVIY) |
Teva will use AutoImmune's technology for oral immune modulation to develop an oral formulation of Copaxone (glatiramer acetate) for multiple sclerosis and a product to treat myasthenia gravis |
$20M |
Teva to pay milestones upon product approvals and escalating royalties based on cumulative sales for all products covered by the agreement (2/23) |
Aviron |
Wyeth Ayerst Laboratories (wholly owned subsidiary of American Home Products; NYSE: AHP) |
Worldwide collaboration for the marketing of FluMist, Aviron's intranasal influenza vaccine |
$400M |
Wyeth Lederle Vaccines business unit gains exclusive worldwide marketing rights; Wyeth and Aviron will co-promote in the U.S., while Wyeth has exclusive rights elsewhere, excluding Korea, Australia, New Zealand and certain South Pacific countries; companies will collaborate on regulatory, clinical and marketing programs; Aviron receives initial license payment of $15M, $15M upon acceptance for filing of NDA, and $20M upon FDA approval; the granting of certain other rights under the license would trigger additional payments in excess of $140M; consideration also includes up to $40M in financing, contingent upon product approval; Aviron will also receive about 40% of product revenues from Wyeth in the form of transfer payments and royalties, which increase at higher sales levels; Aviron will incur expenses to supply and co-promote FluMist (1/12) |
Axis Genetics* |
F. HoffmannLa Roche Ltd. (Switzerland) |
Collaboration to evaluate oral Epicoat vaccines for use in the field of animal nutrition and health applications; partners seeking to determine whether oral administration of the vaccines, created with Axis' Chimaeric Virus Particle technology, can stimulate mucosal immunity in the gastrointestinal tract of farm animals |
ND |
Agreement includes a fee-bearing option for Roche to obtain a license for use in animal nutrition and health applications; further details ND (3/1) |
Axys Pharmaceuticals Inc. |
Rhone-Poulenc Rorer (NYSE:RP) |
Axys to provide generic compound screening library consisting of multiple small-molecule synthetic organic compound libraries created using Axys' combinatorial chemistry technologies |
ND |
2-year agreement is second between Axys and RPR; terms ND (1/7) |
Bio-Technology General Corp. |
Diosynth (wholly owned subsidiary of Akzo-Nobel NV; the Netherlands) |
Technology transfer and license agreement for BTG's recombinant human insulin |
ND |
BTG will transfer technology to Diosynth, which will manufacture the product in bulk form for licensed territories (most of the world); Akzo Nobel's Organon subsidiary may finish the bulk and market the product; BTG will receive license fees, milestones and royalties (1/12) |
Biovector Therapeutics SA* (France) |
Bayer AG (Germany) |
Feasibility agreement under which Bayer will assess Lipoplex-Biovector Systems to allow functional circulating Factor VIII protein expression |
ND |
Study expected to last 6 months; further details ND (3/16) |
CoCensys Inc. |
Senju Pharmaceutical Co. (Japan) |
Collaboration to explore Ltd. potential ophthalmic indications of glycine-site NMDA and AMPA receptor antagonist compounds |
ND |
ND (2/17) |
Senju Pharmaceutical Co. Ltd. (Japan) and the Parke-Davis Pharmaceutical division of Warner Lambert Co. (NYSE:WLA) |
Collaboration to investigate subtype-selective NMDA receptor antagonist compounds that are being developed for neurological and psychiatric disorders under CoCensys' collaboration with Parke-Davis |
ND |
ND (2/17) |
|
CombiChem Inc. |
Ono Pharmaceutical Co. Ltd. (Japan) |
CombiChem will work with Ono to generate lead drug candidates for a target of interest to Ono; target was selected using CombiChem's Universal Informer Library |
ND |
Ono will pay a project initiation fee, research support and milestones; Ono has exclusive global rights to develop and market or sublicense products resulting from the collaboration; CombiChem is entitled to royalties on resulting products (1/4) |
Connetics Corp. |
Medeva plc (NYSE:MDV; U.K.) |
Development, commercialization and supply agreement for ConXn (recombinant human relaxin) |
$35M (equity; 3-4%) |
Medeva will pay $8M on closing (including $4M development fee and $4M equity investment), $17M in milestones for U.S. and European progress, $5M for development and approval of each indication in Europe in addition to scleroderma, and $10M of U.S. product development costs; Medeva responsible for development and commercialization in Europe; Companies will share U.S. co-promotion rights for up to 5 years; Medeva will purchase relaxin materials from Connetics (1/12) |
Cortex Pharmaceuticals Inc. (OTC BB:CORX) |
NV Organon (pharmaceutical business unit of AkzoNobel NV; the Netherlands) |
Exclusive worldwide license agreement that will enable Organon to develop and commercialize Cortex's Ampakine technology for the treatment of schizophrenia and explore it in the area of depression |
ND |
Agreement includes an up-front payment, R&D payments for 2 years, and milestone payments, plus royalty payments on worldwide sales (1/13) |
Cubist Pharmaceuticals Inc. |
Novartis Pharma AG (Switzerland) |
Novartis to use Cubist's VITA technology (Validation In vivo of Targets and Assays for Anti-infectives) to validate and develop assays for anti-infective targets and to identify new compounds for development as anti-infective agents |
$33M (equity; 5%) |
Novartis to make up-front $4M equity investment in Cubist; Novartis will also provide research funding annually for 3 years, make milestone payments for each high-throughput screen delivered to Novartis and milestone payments for each product developed (2/9) |
CuraGen Corp. |
Hoffmann LaRoche Inc. and Roche Vitamins Inc. (both affilates of F. Hoffmann La-Roche Ltd.; Switzerland) |
CuraGen will apply its pharmacogenomic technology platform to evaluate current product candidates and will provide all Roche research centers with access to gene expression and gene sequence databases through internet-based platform; Roche will integrate information from SeqCalling and GeneCalling into target discovery efforts; research covers both human and animal health |
ND |
Agreement runs 2 years and is renewable; CuraGen receives up-front funding, plus milestones and royalties (3/22) |
Deltagen Inc.* |
Roche Bioscience (unit of F. Hoffmann La-Roche Ltd.; Switzerland) |
Research agreement under which Deltagen will create knockout mice for up to 10 Roche gene targets for use in target validation programs |
ND |
ND (1/6) |
Merck & Co. Inc. (NYSE:MRK) |
Research agreement under which Deltagen will provide target validation using knockout mouse technology |
ND |
ND (1/21) |
|
diaDexus LLC (joint venture between Incyte Pharmaceuticals Inc. and SmithKline Beecham plc; NYSE: SBH; U.K.) |
SmithKline Beecham Corp. (unit of SmithKline Beecham plc; NYSE:SBH;U.K.) |
SmithKline exclusively licensed rights to develop and perform a PLA2 test, which determines whether prostate cancer has spread |
ND |
SmithKline gains certain exclusive rights in the U.S. and several international markets to develop and perform clinical laboratory testing for PLA2; diaDexus will receive licensing fees as well as royalties on sales (2/25) |
Epoch Pharmaceuticals Inc. (OTC BB:EPPH) |
PE BioSystems (division of Perkin-Elmer Corp.; NYSE:PKN) |
PE licensed genetic analysis technology from Epoch and will purchase Epoch's proprietary chemical intermediates |
ND |
Perkin-Elmer will pay up-front license fees and pre-payments for future purchases, along with royalties on products incorporating the technology (1/11) |
Exelixis Pharmaceuticals Inc.* (Exelixis-affiliated Artemis Pharmaceuticals GmbH* [Germany] also expected to participate) |
Pharmacia & Upjohn (NYSE: PNU) |
Research collaboration to identify targets for small-molecule therapeutics in the areas of Alzheimer's disease and Metabolic Syndrome, including diabetes and obesity; Exelixis will utilize PathFinder technology coupled with genomic and computational biology techniques to identify targets |
ND |
Collaboration is for 5 years; Exelixis will receive an up-front payment, research support, and royalties on sales; Exelixis retains rights to develop small-molecule therapeutics outside the field of the sponsored research as well as in the field(s) of research for targets not selected by P&U (3/3) |
ExonHit Therapeutics SA* (France) |
Sosei Co. Ltd. |
Sosei to serve as R&D partner and independent, non-exclusive adviser to ExonHit in negotiating commercial partnerships with Asian companies covering any or all of research, development, manufacture, marketing and distribution activities for ExonHit's genomic products, including gene profiling; ExonHit will also use its DATAS (Differential Analysis of Transcripts Alternatively Spliced) technology on "me too" molecules from Japanese companies to highlight how the molecules differ from competing compounds |
ND |
ND (2/5) |
Gene Logic Inc. |
Japan Tobacco Inc. |
Gene Logic will use its READS gene expression and bioinformatics technologies to identify drug targets for an undisclosed therapeutic area |
$12M |
Gene Logic will receive a minimum of $12M in committed revenues and is entitled to milestones of about $17M for each product resulting from use of technologies, plus royalties (1/4) |
Genentech Inc. |
Schwarz Pharma AG (Germany) |
Development and distribution agreement for Nutropin AQ (somatropin, rDNA origin, for injection) and Nutropin Depot (somatropin, rDNA origin, for depot suspension); both are growth hormones for treatment of adult and pediatric growth disorders |
ND |
Schwarz gains exclusive rights to import, distribute and develop Nutropin AQ and Nutropin Depot in Europe and certain other countries outside the U.S., Canada and Japan; Schwarz will file applications for both in Europe(1/29) |
Genetics Institute Inc. (wholly owned subsidiary of American Home Products Corp.; NYSE:AHP) |
Rhone-Poulenc Rorer (NYSE:RP) |
RPR joined GI's Discover-Ease program, which provides access to Discover-Ease protein library of human secreted proteins, the corresponding genes, and a relational database of associated information; RPR will analyze the genes and proteins to identify small-molecule drug targets and genes and proteins with potential applications in gene therapy and vaccines |
ND |
ND (3/5) |
Genetics Institute Inc. (wholly owned subsidiary of American Home Products Corp.; NYSE:AHP) |
Sankyo Co. Ltd. (Japan) |
Sankyo joined GI's Discover-Ease program, which provides access to Discover-Ease protein library of human secreted proteins, the corresponding genes, and a relational database of associated information; Sankyo will analyze the genes and proteins to identify small-molecule drug targets and genes and proteins with potential therapeutic applications |
ND |
GI will receive an up-front library access fee and possible downstream fees based on the successful development and commercialization of therapeutics (3/5) |
Genetix Pharmaceuticals Inc.* |
Cordis (subsidiary of Johnson & Johnson; NYSE:JNJ) |
R&D collaboration on gene therapy products to treat cardiovascular disease by means of angiogenesis; initial phase will center on evaluation of several angiogenic genes and gene-delivery methods; research will utilize Genetix's gene transfer systems and the NOGA intracardiac navigational catheter system developed by J&J's Biosense Webster subsidiary |
ND |
Cordis will provide research funding to Genetix with an option to extend it in the future; Genetix would grant a royalty-bearing license to Cordis to develop and market therapies (1/28) |
Genometrix Inc.* |
Motorola Inc. (NYSE:MOT) |
Motorola obtained a non-exclusive license to certain fundamental DNA chip intellectual property for the commercialization of portable DNA-based diagnostic systems |
ND (equity; % ND) |
Combined equity financing and license option agreements; Motorola bought an undisclosed amount of Genometrix preferred stock and obtained an option for a nonexclusive license (1/21) |
ILEX Oncology Inc. |
Eli Lilly and Co. (NYSE:LLY) |
ILEX will develop Lilly's diarysulfonylurea, LY295501, an anticancer compound; Lilly has option to further develop and commercialize the molecule after completion of certain clinical trials; if Lilly declines the option, ILEX gets the rights |
ND (equity; %ND) |
ILEX will pay Lilly milestones and royalties on sales in addition to a license fee (1/26) |
ImmunoGen Inc. |
SmithKline Beecham plc (NYSE:SBH; U.K.) |
SmithKline to develop and commercialize Immuno-Gen's lead tumor-activated prodrug, huC242-DM1 |
>$40M (equity; appro- |
ImmunoGen could receive up-front cash and milestones of more than $40M, plus royalties; at ImmunoGen's option, Smith- line will purchase up to $5M of common stock over the next 2 years; Smith-Kline receives exclusive worldwide rights to commercialize huC242-DM1, except in certain Far East territories (2/3) |
Inflazyme Pharmaceuticals Ltd. |
Hoechst Marion Roussel Inc. (subsidiary of Hoechst AG; Germany) |
R&D collaboration on HMR's H1/NK1 inhibitor (a single molecule combining an antihistamine and a second anti-allergic mediator) and a compound from Inflazyme's IPL576 class; Inflazyme will be responsible for development of both through Phase IIa; HMR will then have the option to take over further development and commercialization of the oral form of the H1/NK1 inhibitor and the IPL576 comopound; the companies will also collaborate on discovery of the mode of action and cellular target of IPL576 |
$91M |
HMR would get worldwide rights (except Canada) for a compound from Inflazyme's IPL576 class for the treatment of respiratory disease and asthma; Inflazyme would receive a license to develop oral and topical forms of HMR's H1/NK1 inhibitor as a treatment for allergies; HMR will have the option to take over further development and commercialization of the IPL576 compound and the oral form of the H1/NK1 inhibitor (with Inflazyme retaining rights to any topical ocular formulation of the inhibitor); Inflazyme receives up front licensing fee and equity investment by HMR totaling $16M, plus milestones of $75M and royalties; Inflazyme has rights to discoveries made in research into mode of action and target for IPL576 until HMR takes over development (2/9) |
InSite Vision Inc. |
Pharmacia & Upjohn Inc. (NYSE:PNU) |
P&U licensed ISV-205, which contains diclofenac (non-steroidal anti-inflammatory drug) delivered to the eye using sustained-release DuraSite technology; P&U will assume responsibility for development upon completion of Phase II studies currently being conducted by InSite |
ND (equity; % ND) |
InSite receives equity investment from P&U, potential future milestone-based equity investments, payments for ongoing technical support and royalty payments on sales (1/18) |
Isis Pharmaceuticals |
Abbott Laboratories (NYSE:ABT) |
Abbott will use Isis' Anti-sense Target Validation technology to prioritize drug development gene targets; Isis will design, screen, synthesize and characterize inhibitors of gene targets provided by by Abbott |
ND |
Isis will receive an up-front fee, quarterly research fees, milestones and royalties on net sales of any Abbott non-antisense product arising from the collaboration; Isis gets rights to Abbott genes to develop antisense drugs (1/12) |
LeukoSite |
Warner-Lambert Co. (NYSE:WLA) |
Agreement to discover and develop small-molecule antagonists to 2 integrin targets implicated in asthma and inflammatory bowel disease |
>$100M |
LeukoSite will receive license fees, research support and milestone payments that could exceed $50M for each of the 2 integrin targets, in addition to royalties (1/11) |
LXR Biotechnology Inc. |
RPR Gencell (division of Rhone-Poulenc Rorer Inc.; subsidiary of Rhone-Poulenc SA; NYSE:RP; France) |
RPR Gencell will evaluate the cytoprotective role of the SARP-1 gene, discovered by LXR, in heart muscle cells that have been deprived of oxygen |
ND |
RPR has right right of first negotiation to acquire the rights to SARP-1 related technology for cardiovascular indications (1/7) |
Metabolex Inc. |
Parke-Davis (division of Warner-Lambert Co.; NYSE:WLA) |
Research collaboration to discover and develop therapeutics that counteract insulin secretion defects in type 2 diabetes |
>$50M (equity; %ND) |
Metabolex will receive an up-front research fee and equity investment, as well as milestones and royalties; pre-commercialization payments could exceed $50M (1/6) |
Millennium Predictive Medicine Inc. (wholly owned subsidiary of Millennium Pharmaceuticals Inc.) |
Becton Dickinson and Co. (NYSE:BDX) |
Five year alliance to develop Diagnomic (molecular diagnostics) and pharmacogenomic tests for cancer patients |
$69.5M (equity; 11% voting interest) |
Becton Dickinson will provide $15M in equity investment (for an 11% voting interest), a $3M licensing fee, and up to $51.5M in research funding and additional annual licensing fees; Millennium Predictive will receive milestones and royalties on sales (2/22) |
NaviCyte Inc. (wholly owned subsidiary of Trega Biosciences Inc.) |
Schering-Plough Corp. (NYSE:SGP) |
Collaboration on use and development of NaviCyte's Pk (pharmacokinetics) informatics tools to identify drug candidates; Schering-Plough joins consortium supporting development of NaviCyte's In Vitro Determination for Evaluation of Adsorption (IDEA) simulation software system and database; IDEA aims to predict in silico the ADME characteristics of drugs (adsorption, distribution, metabolism and excretion) |
ND |
Schering-Plough will provide data for IDEA and make initial and milestone payments over the course of development of the software and database; NaviCyte will license to Schering-Plough its software and computational models for use with Schering-Plough compound libraries. (3/9) |
NeoPharm Pharmaceuticals Inc. |
Pharmacia & Upjohn Inc. (NYSE:PNU) |
Definitive agreement for development and commercialization of 2 cancer products: Liposomal Encapsulated Paclitaxel (LEP) and Liposomal Encapsulated Doxorubicin (LED); companies will also work together to identify additional P&U oncology drugs that can be reformulated into NeoPharm's liposome technology |
$65M |
NeoPharm receives $15M up front as well as milestones in excess of $50M; P&U will pay for all clinical and premarketing expenses; NeoPharm will also receive royalty payments overseas and a co-promotion profit split in the U.S.; P&U gains exclusive worldwide marketing rights (2/22) |
Neurocrine Biosciences Inc. |
Wyeth-Ayerst Laboratories (subsidiary of American Home Products Corp.;NYSE:AHP) |
R&D and commercialization agreement on compounds that modulate excitatory amino acid transporters for the treatment of neurodegenerative and psychiatric diseases; companies will share proprietary technologies, including Wyeth's combinatorial chemistry libraries, for screening within the collaborative field |
$78M |
Neurocrine expects to receive 3 to 5 years of R&D funding, milestones and royalties on resulting products (3/2) |
Ontogeny Inc.* |
Tropix (unit of PE Biosystems; subsidiary of Perkin-Elmer Corp.; NYSE:PKN) |
Ontogeny transfered assays for a number of validated targets to Tropix for ultra-high-throughput screening under Xtreme Screen program; the aim is to identify classes of small-molecule leads and extract value from Ontogeny's programs, including the use of small-molecule receptors and pathways; Tropix will screen combinatorial compound libraries for activity against Ontogeny targets, and will optimize assays to run under ultra-high-throughput screening conditions |
ND |
ND (1/21) |
Pharmacopeia Inc. |
Pharmacia & Upjohn Inc. (NYSE:PNU) |
Pharmacopeia will screen its multi-million compound sample collection of diverse, small molecules against P&U targets; optimization of active compounds may be performed by P&U or by Pharmacopeia, for additonal consideration |
ND |
Multi-year agreement with guaranteed annual payments and further payments based on the success of the screening programs (1/19) |
ProCyte Corp. |
Neutrogena Corp. (subsidiary of Johnson & Johnson; NYSE:JNJ) |
Neutrogena will evaluate ProCyte's copper peptide complexes for hair and skin products |
ND |
Companies signed 2 agreements; the first is an option and product study agreement for ProCyte's AHK:cu technology for consumer hair products; the second is a product study agreement for ProCyte's GHK:cu technology for skin care products (2/3) |
Quark Biotech Inc.* |
Sankyo Co. Ltd. (Japan) |
Sankyo will use Quark's pathology-specific gene discovery technology and model systems to study gene responses and identify candidates for type 2 diabetes; Quark will initially conduct a feasibility study to determine the insulin response pathways in specific target cells; over long term, Quark will perform high-throughput gene discovery using functional and differential expression profiling in animal models |
ND |
Payments to Quark include milestones and royalties (2/16) |
Rigel Inc.* |
Janssen Pharmaceutica NV (subsidiary of Johnson & Johnson; NYSE:JNJ) |
Collaboration to identify drug targets that control progression of cancer based on Rigel's functional genomics technology; efforts will focus on discovery and validation of small-molecule drug targets that regulate cell cycle; collaboration also covers predictive, diagnostic and protein therapeutic utility of targets |
ND (equity; % ND) |
Janssen will provide research funding for a minimum of 3 years, as well as a cash up-front payment and milestones; Rigel would also receive royalties; the Johnson & Johnson Development Corp. is participating in Rigel's Series D financing; Janssen gets exclusive worldwide rights to develop and market drugs against the cell cycle regulating targets and will also have nonexclusive rights to the use of some Rigel technology to discover targets in other areas of cancer therapy in exchange for milestones and royalties on sales (1/14) |
Ribozyme Pharmaceuticals Inc. |
Eli Lilly and Co. (NYSE:LLY) |
Collaboration on R&D and commercialization of ribozymes for the treatment of hepatitis C virus infection |
$38M |
Ribozyme will receive $9.2M in 1999, including initial fees, research funding, funding for clinical trial materials and an equity investment; Ribozyme could eventually receive up to $38M (mostly from milestones), plus product royalties (3/23) |
Sangamo BioSciences Inc.* |
DuPont Pharmaceuticals Co. (NYSE:DD) |
DuPont will use Sangamo's Universal GeneTools platform in the identification and validation of gene targets for drug discovery; platform enables rational design and rapid generation of ZFP transcription factors that can recognize and regulate target gene or DNA sequence |
ND |
DuPont will provide funding in exchange for using Sangamo's technology (1/14) |
Japan Tobacco Inc. |
Japan Tobacco will use Sangamo's Universal Gene-Tools platform in the identification and validation of gene targets for drug discovery; platform enables rational design and rapid generation of ZFP transscription factors that can recognize and regulate target gene or DNA sequence |
ND |
Japan Tobacco will provide funding in exchange for using Sangamo's technology (3/9) |
|
Scriptgen Pharmaceuticals Inc.* |
DuPont Pharmaceuticals Co. (NYSE:DD) |
Antibacterials collaboration; collaboration includes transfer of Scriptgen's lead series of antibacterial compounds as well as screening of compounds from both Scriptgen's and DuPont's compound libraries; Scriptgen will provide access to its ATLAS and SCAN assay technologies to identify compounds that bind to protein or RNA targets respectively, and to its GATE technology, a family of high-throughput target and validation technologies; DuPont is responsible for lead optimization chemistry and all preclinical and clinical development |
$53M (equity; % ND) |
DuPont committed $8M to gain access to Scriptgen's assay, screening and validation technologies; the $8M combines an up-front payment and purchase of Scriptgen capital stock at the time of its IPO; Scriptgen will also receive research and milestone payments and royalties on products; with 2 successful products, the total could exceed $53M plus royalties (1/7) |
Targacept Inc. (wholly owned subsidiary of R.J. Reynolds Tobacco Co., a subisidary of RJR Nabisco Inc.; NYSE:RN) |
Rhone-Poulenc Rorer Inc. (subsidiary of Rhone-Poulenc SA; NYSE:RP; France) |
Collaboration on R&D and commercialization of certain nicotinic compounds for Alzheimer's and Parkinson's diseases |
ND (potential equity) |
RPR has exclusive global rights to compounds covered in the collaboration; Targacept will receive license fees, milestones and royalties, as well as a potential equity investment (2/9) |
Techniclone Corp. |
Schering AG (Germany) |
Collaboration on Techniclone's Oncolym, a radio-labeled monoclonal anti-body in Phase II/III for the treatment of intermediate and high-grade non-Hodgkin's B-cell lymphoma |
$20M |
Schering will pay Techniclone a $3M up-front fee, plus $17M for milestones and capital costs for commercial radiolabeling scale-up; Schering will also assume 80% of the existing clinical trial costs and pay royalties; Techniclone will manufacture the drug and receive a margin above production cost; Schering gets exclusive worldwide marketing/distribution rights (3/9) |
Transkaryotic Therapies Inc. |
Sumitomo Pharmaceuticals Co. Ltd. (Japan) |
Collaboration to commercialize Transkaryotic's alpha-galactosidase A enzyme replacement therapy for Fabry disease in Japan and other Far East territories |
$2M |
Sumitomo paid Transkaryotic $2M up front and will make additional payments as the product moves through development and commercialization (1/13) |
Xenometrix Inc. (OTC BB:XENO) |
SmithKline Beecham plc (NYSE:SBH; U.K.) |
Xenometrix granted SmithKline nonexclusive license to gene profiles utilizing all methods including high-density microarrays |
ND |
ND |
| NOTES: # This chart contains information on new agreements, covering the time between 1/1/99 and 3/23/99. It does not include arrangements that are classified strictly as production, manufacturing, marketing and/or distribution and supply agreements; a chart covering these arrangements will appear in the 4/12/99 issue of BioWorld Financial Watch. The chart above also does not include any collaborations that involve agricultural product development (which are covered periodically in this publication). A chart covering modified agreements and terminated agreements between big pharma and biotech companies for the same time period (1/1/99 to 3/23/99) will also appear in the 4/12/99 issue of BioWorld Financial Watch. AIM = Alternative Investment Market (U.K.); LSE = London Stock Exchange; ND = Not disclosed, reported and/or available * Private companies are indicated with an asterisk. ** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock report For Public Biotechnology Companies on pp. 16-17. | ||||
